These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 33628506)

  • 1. A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Moderate COVID-19 Infections.
    Purwati ; Budiono ; Rachman BE; Yulistiani ; Miatmoko A; Nasronudin ; Lardo S; Purnama YI; Laely M; Rochmad I; Ismail T; Wulandari S; Setyawan D; Rosyid AN; Setiawan HW; Wulaningrum PA; Asmarawati TP; Marfiani E; Yuniati SK; Fuadi MR; Endraswari PD; Purwaningsih ; Hendrianto E; Karsari D; Dinaryanti A; Ertanti N; Ihsan IS; Purnama DS; Indrayani Y
    Biochem Res Int; 2021; 2021():6685921. PubMed ID: 33628506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19.
    Echarte-Morales J; Minguito-Carazo C; Del Castillo-García S; Borrego-Rodríguez J; Rodríguez-Santamarta M; Sánchez-Muñoz E; Bergel-García R; González-Maniega C; Prieto-González S; Menéndez-Suarez P; Tundidor-Sanz E; Benito-González T; Fernández-Vázquez F
    J Electrocardiol; 2021; 64():30-35. PubMed ID: 33307378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital.
    Gourieux B; Reisz F; Belmas AS; Danion F; Fourtage M; Nai T; Reiter-Schatz A; Ruch Y; Walther J; Nivoix Y; Michel B
    Eur J Hosp Pharm; 2021 Sep; 28(5):242-247. PubMed ID: 33239282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
    Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
    Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial.
    Reis G; Moreira Silva EADS; Medeiros Silva DC; Thabane L; Singh G; Park JJH; Forrest JI; Harari O; Quirino Dos Santos CV; Guimarães de Almeida APF; Figueiredo Neto AD; Savassi LCM; Milagres AC; Teixeira MM; Simplicio MIC; Ribeiro LB; Oliveira R; Mills EJ;
    JAMA Netw Open; 2021 Apr; 4(4):e216468. PubMed ID: 33885775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
    Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
    Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of combined treatment of 3rd-generation cephalosporin, azithromycin and antiviral agents on moderate SARs-CoV-2 patients in South Korea: A retrospective cohort study.
    Hong W; Park YK; Kim BO; Park SK; Shin J; Jang SP; Park HW; Yang W; Jang J; Jang SW; Hwang TH
    PLoS One; 2022; 17(5):e0267645. PubMed ID: 35507600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis.
    Lecronier M; Beurton A; Burrel S; Haudebourg L; Deleris R; Le Marec J; Virolle S; Nemlaghi S; Bureau C; Mora P; De Sarcus M; Clovet O; Duceau B; Grisot PH; Pari MH; Arzoine J; Clarac U; Boutolleau D; Raux M; Delemazure J; Faure M; Decavele M; Morawiec E; Mayaux J; Demoule A; Dres M
    Crit Care; 2020 Jul; 24(1):418. PubMed ID: 32653015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of corticosteroids therapy in patients with moderate to severe SARS-CoV-2 infection: a multicenter, randomized, open-label trial.
    Ghanei M; Solaymani-Dodaran M; Qazvini A; Ghazale AH; Setarehdan SA; Saadat SH; Ghobadi H; Hoseininia S; Elahikhah M; Samadi AH; Imani Y; Vahedi E; Babamahmoodi F; Rostami FT; Ardebili MHA; Ansarifar A; Golmaei FF; Asadollah A
    Respir Res; 2021 Sep; 22(1):245. PubMed ID: 34526033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study.
    Huang YQ; Tang SQ; Xu XL; Zeng YM; He XQ; Li Y; Harypursat V; Lu YQ; Wan Y; Zhang L; Sun QZ; Sun NN; Wang GX; Yang ZP; Chen YK
    Front Pharmacol; 2020; 11():1071. PubMed ID: 32765274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.
    Vahedi E; Ghanei M; Ghazvini A; Azadi H; Izadi M; Panahi Y; Fathi S; Salesi M; Saadat SH; Ghazale AH; Rezapour M; Mozafari A; Zand N; Parsaei MR; Ranjkesh MH; Jafari R; Movaseghi F; Darabi E
    Daru; 2020 Dec; 28(2):507-516. PubMed ID: 32562159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atorvastatin therapy in COVID-19 adult inpatients: A double-blind, randomized controlled trial.
    Davoodi L; Jafarpour H; Oladi Z; Zakariaei Z; Tabarestani M; Ahmadi BM; Razavi A; Hessami A
    Int J Cardiol Heart Vasc; 2021 Oct; 36():100875. PubMed ID: 34541293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses.
    Kang CK; Seong MW; Choi SJ; Kim TS; Choe PG; Song SH; Kim NJ; Park WB; Oh MD
    Korean J Intern Med; 2020 Jul; 35(4):782-787. PubMed ID: 32460458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of COVID-19 with mild-to-moderate severity: A retrospective observational study.
    Lee JE; Lee SO; Heo J; Kim DW; Park MR; Son H; Kim D; Kim KH; Lee S; Lee SH
    Antivir Ther; 2021; 26(1-2):34-42. PubMed ID: 35485345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Darunavir: a review of its use in the management of HIV infection in adults.
    McKeage K; Perry CM; Keam SJ
    Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis.
    Amani B; Khanijahani A; Amani B; Hashemi P
    J Pharm Pharm Sci; 2021; 24():246-257. PubMed ID: 34048671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.